Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tactile Systems TechnologyTCMD -2.55%74 Debt-to-EBITDA is 4.92 as of Mar. 2026, which is 254% above its 10-year median of 1.39. GuruFocus rates TCMD with a GF Score™ of 74/100 and a GF Value™ of $18.78 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 469 Medical Devices & Instruments companies, Tactile Systems Technology ranks better than 77.19% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Tactile Systems Technology's Debt-to-EBITDA or its related term are showing as below:
TCMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -25.65 Med: 1.39 Max: 41.59
Current: 0.36
During the past 13 years, the highest Debt-to-EBITDA Ratio of Tactile Systems Technology was 41.59. The lowest was -25.65. And the median was 1.39.
TCMD's Debt-to-EBITDA is ranked better than 77.19% of 469
companies
in the Medical Devices & Instruments industry
Industry Median: 1.6
vs TCMD: 0.36
Tactile Systems Technology (NAS:TCMD) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Tactile Systems Technology Debt-to-EBITDA Related Terms
Tactile Systems Technology Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCMD vs SSII, BVS, BBNX: Debt-to-EBITDA Comparison
For the Medical Devices subindustry, Tactile Systems Technology's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tactile Systems Technology Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tactile Systems Technology's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Tactile Systems Technology's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Tactile Systems Technology (TCMD) has a Debt-to-EBITDA of 4.92 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tactile Systems Technology. This is 254% above median its historical median of 1.39. According to the industry distribution chart, Tactile Systems Technology ranks #107 out of 469 companies in the Medical Devices & Instruments industry, placing it in the top 22.8%.
Is Tactile Systems Technology's Debt-to-EBITDA too high?
Tactile Systems Technology's current Debt-to-EBITDA of 4.92 is 254% above median its 10-year median of 1.39. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. Tactile Systems Technology's value of 4.92 is 207.5% above this industry median. Based on the distribution chart, Tactile Systems Technology ranks #107 out of 469 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tactile Systems Technology has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Tactile Systems Technology's Debt-to-EBITDA compare to SSII and BVS?
According to the Medical Devices & Instruments industry distribution chart, Tactile Systems Technology ranks #107 out of 469 companies for Debt-to-EBITDA. This places Tactile Systems Technology in the top 23% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.60. Tactile Systems Technology's value of 4.92 is 207.5% above this benchmark. While the company's 10-year median is 1.39 vs. the industry median of 1.60, Tactile Systems Technology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 469 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tactile Systems Technology's current Debt-to-EBITDA of 4.92 is 207.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Tactile Systems Technology. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tactile Systems Technology's current Debt-to-EBITDA is 4.92, which is 254% above median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tactile Systems Technology stock overvalued right now?
Based on GuruFocus' analysis, Tactile Systems Technology (TCMD) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.78, compared to a current price of $28.67 — trading 52.7% above its estimated fair value. The current Debt-to-EBITDA is 4.92, which is 254% above median its 10-year median of 1.39 and 207.5% above the Medical Devices & Instruments industry median of 1.60. Tactile Systems Technology's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Tactile Systems Technology (TCMD), the current Debt-to-EBITDA is 4.92 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tactile Systems Technology (TCMD) Overvalued in 2026?
Based on GuruFocus' analysis, Tactile Systems Technology stock appears to be overvalued.
The current stock price of $28.67 is trading 52.7% above its estimated GF Value™ of $18.78.
GuruFocus considers Tactile Systems Technology to be Significantly Overvalued.
Key valuation signals for TCMD:
Debt-to-EBITDA: 4.92 (254% above median its 10-year median of 1.39)
GF Value™: $18.78 vs. price of $28.67 (52.7% above fair value)
Industry Position: 207.5% above the Medical Devices & Instruments median (#107 of 469)
No single metric tells the full story. See the TCMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
74GF Score
Get the complete analysis for TCMD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCMD has been successfully added to your 
